Tigermed Sets 2025 AGM to Decide Dividends, Board Mandates and Governance Changes

An update from Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) is now available.

Hangzhou Tigermed Consulting Co., Ltd. has called its 2025 annual general meeting for June 2, 2026 in Hangzhou, where shareholders will review the 2025 operating year, including the annual report, board report, final financial report and profit distribution plan. Investors will also vote on appointing the 2026 auditor and approving an application for an integrated bank credit facility, decisions that will shape the company’s capital resources and financial oversight for the coming year.

The AGM agenda further includes resolutions to set and formalize remuneration standards and a management system for directors and senior executives, as well as to amend the articles of association. Shareholders are also being asked to grant the board general mandates to issue and repurchase H shares and to re-elect key executive and independent non-executive directors for a new board term, moves that will influence Tigermed’s governance structure, capital flexibility and long‑term strategic direction.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

More about Hangzhou Tigermed Consulting Co., Ltd. Class H

Hangzhou Tigermed Consulting Co., Ltd. is a China-based provider of clinical research and related consulting services for the pharmaceutical and medical sectors. Listed in Hong Kong as a Class H share issuer, the company focuses on supporting drug development and regulatory compliance for domestic and international clients.

Average Trading Volume: 1,814,582

Technical Sentiment Signal: Sell

Current Market Cap: HK$49.1B

Learn more about 3347 stock on TipRanks’ Stock Analysis page.